These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22975016)

  • 21. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global adaptation of IADPSG recommendations: a national approach.
    Lieberman N; Kalter-Leibovici O; Hod M
    Int J Gynaecol Obstet; 2011 Nov; 115 Suppl 1():S45-7. PubMed ID: 22099442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of cervical-cancer screening in five developing countries.
    Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
    N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic impact of routine opt-out antenatal human immune deficiency virus screening: A systematic review.
    Ibekwe E; Haigh C; Duncan F; Fatoye F
    J Clin Nurs; 2017 Dec; 26(23-24):3832-3842. PubMed ID: 28252818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
    Okeah BO; Ridyard CH
    Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effective screening method for preoperative hyperglycemia.
    Grek S; Gravenstein N; Morey TE; Rice MJ
    Anesth Analg; 2009 Nov; 109(5):1622-4. PubMed ID: 19843800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cervical cancer screening - The challenges of complete pathways of care in low-income countries: Focus on Malawi.
    Cubie HA; Campbell C
    Womens Health (Lond); 2020; 16():1745506520914804. PubMed ID: 32364058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economics in developing countries.
    Abel-Smith B
    J Trop Med Hyg; 1989 Aug; 92(4):229-41. PubMed ID: 2503621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany.
    Schaufler TM; Wolff M
    Appl Health Econ Health Policy; 2010; 8(3):191-202. PubMed ID: 20408603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries.
    Lansdorp-Vogelaar I; Meester RGS; Laszkowska M; Escudero FA; Ward ZJ; Yeh JM
    Best Pract Res Clin Gastroenterol; 2021; 50-51():101735. PubMed ID: 33975689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developments in the screening for Chlamydia trachomatis: a review.
    Kohl KS; Markowitz LE; Koumans EH
    Obstet Gynecol Clin North Am; 2003 Dec; 30(4):637-58. PubMed ID: 14719842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary prevention of type-2 diabetes in developing countries.
    Dagogo-Jack S
    J Natl Med Assoc; 2006 Mar; 98(3):415-9. PubMed ID: 16573308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
    Critselis E; Vlahou A; Stel VS; Morton RL
    Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV screening in pregnant women: A systematic review of cost-effectiveness studies.
    Bert F; Gualano MR; Biancone P; Brescia V; Camussi E; Martorana M; Thomas R; Secinaro S; Siliquini R
    Int J Health Plann Manage; 2018 Jan; 33(1):31-50. PubMed ID: 28556453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.
    Pimple SA; Mishra GA
    Minerva Ginecol; 2019 Oct; 71(5):365-371. PubMed ID: 31698891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes during Pregnancy in Low- and Middle-Income Countries.
    Goldenberg RL; McClure EM; Harrison MS; Miodovnik M
    Am J Perinatol; 2016 Nov; 33(13):1227-1235. PubMed ID: 27182990
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.